You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 30, 2025

Patent: 10,206,910


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,206,910
Title:Apilimod for use in the treatment of renal cancer
Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
Inventor(s): Beeharry; Neil (Guilford, CT), Gayle; Sophia (East Haven, CT), Landrette; Sean (Meriden, CT), Beckett; Paul (Yorktown Heights, NY), Conrad; Chris (Guilford, CT), Xu; Tian (Guilford, CT), Rothberg; Jonathan M. (Guilford, CT), Lichenstein; Henri (Guilford, CT)
Assignee: LAM Therapeutics, Inc. (Guilford, CT)
Application Number:15/524,844
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,206,910

Introduction

When analyzing a patent, such as United States Patent 10,206,910, it is crucial to delve into the specifics of the claims, the broader patent landscape, and the legal and practical implications surrounding the patent. This analysis will cover key aspects including the types of claims, distinctiveness, patent assertion entities, and the complexities of patent prosecution.

Understanding Patent Claims

Patent claims are the heart of any patent application, defining the scope of the invention and what is protected under the patent. There are different types of claims, each with its own level of distinctiveness:

Types of Claims

  • Generic Claims: These are the least distinctive and refer to the common name of a product or service. For example, a term like "hotel reservation" would be generic and not eligible for trademark registration[1].
  • Descriptive Claims: These describe the characteristics or features of the product or service but are not inherently distinctive. They can be registered if they acquire secondary meaning, meaning they become distinctive in the minds of consumers[1].
  • Suggestive Claims: These suggest the nature of the product or service without directly describing it. They are more distinctive than descriptive claims and can be registered without needing to prove secondary meaning.
  • Arbitrary Claims: These are words that do not have any inherent meaning related to the product or service. They are highly distinctive and easily registrable.
  • Fanciful Claims: These are invented words that have no meaning other than as a trademark. They are the most distinctive and readily registrable[1].

Patent 10,206,910: A Case Study

To analyze the specific claims of United States Patent 10,206,910, one would need to review the patent document itself. However, here are some general considerations:

Claim Construction

The claims of a patent are interpreted in light of the specification and the prosecution history. The patent office and courts look at the claims as a whole, rather than isolating individual words or phrases. This holistic approach ensures that the claims are understood in the context of the invention[1].

Distinctiveness and Secondary Meaning

For descriptive claims, proving secondary meaning is crucial. This involves showing that the mark has become distinctive in the minds of consumers, such as in the case of "Booking.com," where the term became associated with a specific online hotel-reservation service[1].

Patent Assertion Entities (PAEs)

PAEs, also known as non-practicing entities (NPEs), play a significant role in the patent landscape. They acquire patents not to use them in their own products but to assert them against other companies.

Types of PAEs

  • Portfolio PAEs: These entities negotiate licenses covering large portfolios of patents, often without first suing the alleged infringer. They generate significant revenue from these licenses, typically in the millions of dollars[3].
  • Litigation PAEs: These entities primarily assert patents through litigation. They account for a large percentage of patent infringement suits and often precede licenses with litigation[3].

Patent Prosecution and Term Adjustments

The process of patent prosecution involves several complexities, including the potential for patent term adjustments (PTAs) and the risk of obviousness-type double patenting (ODP).

Patent Term Adjustments

PTAs compensate applicants for delays caused by the Patent Office during prosecution, extending the term of the patent. However, as seen in the In re Cellect case, PTAs can lead to issues with ODP if not properly managed. The Federal Circuit emphasized the importance of filing terminal disclaimers to avoid unjustified extensions of patent terms[2].

Obviousness-Type Double Patenting

ODP prevents a subsequent patent from being granted on the same invention as an earlier granted patent or an obvious modification thereof. The In re Cellect case highlights the need for patent owners to be proactive in addressing ODP during prosecution to avoid invalidation of their patents[2].

Probability of Receiving a U.S. Patent

The probability of receiving a U.S. patent is influenced by several factors, including the type of application, the technology field, and the prosecution history.

Allowance Rates

Studies have shown that the allowance rates for patent applications vary. For instance, the first-action allowance rate, progenitor allowance rate, and family allowance rate provide different insights into the likelihood of a patent being granted. These rates are affected by the complexity of the examination process and the use of continuation applications[4].

Legal and Practical Implications

Consumer Perception

The eligibility for registration of a patent or trademark often turns on consumer perception. The Lanham Act focuses on whether the mark distinguishes goods or services in commerce, emphasizing the primary significance of the mark to the relevant public[1].

Transparency and Accountability

In the context of PAEs, transparency is a significant issue. The FTC study highlighted that PAEs often operate through complex structures, making it difficult to track their activities. Ensuring transparency and accountability is crucial for maintaining a fair patent system[3].

Key Takeaways

  • Claim Distinctiveness: The distinctiveness of patent claims is critical for their registrability and enforceability.
  • PAE Activities: PAEs can significantly impact the patent landscape through licensing and litigation activities.
  • Patent Prosecution: Managing patent term adjustments and addressing ODP are essential during patent prosecution.
  • Consumer Perception: Consumer perception plays a vital role in determining the registrability and enforceability of patents and trademarks.
  • Transparency: Ensuring transparency in PAE activities is important for maintaining a fair and balanced patent system.

FAQs

Q1: What is the difference between generic and descriptive claims?

  • Generic claims refer to the common name of a product or service and are not registrable, while descriptive claims describe the characteristics of a product or service but can be registered if they acquire secondary meaning.

Q2: How do Patent Assertion Entities (PAEs) operate?

  • PAEs operate by acquiring patents to assert them against other companies, either through licensing (Portfolio PAEs) or litigation (Litigation PAEs).

Q3: What is the significance of patent term adjustments (PTAs)?

  • PTAs extend the term of a patent to compensate for delays caused by the Patent Office during prosecution, but they can lead to issues with obviousness-type double patenting if not properly managed.

Q4: How does consumer perception affect patent and trademark registration?

  • Consumer perception is crucial as it determines whether a mark distinguishes goods or services in commerce, affecting its registrability and enforceability.

Q5: What are the implications of obviousness-type double patenting (ODP)?

  • ODP prevents a subsequent patent from being granted on the same invention as an earlier granted patent or an obvious modification thereof, and failing to address ODP during prosecution can lead to the invalidation of patents.

Sources

  1. Patent And Trademark Office v. Booking.com B. V. - Supreme Court of the United States, June 30, 2020.
  2. Federal Circuit Puts the Onus on Patent Owners to Disclaim - Mintz, September 7, 2023.
  3. Patent Assertion Entity Activity: An FTC Study - Federal Trade Commission.
  4. What Is the Probability of Receiving a US Patent? - The Yale Journal of Law & Technology, Vol. 17.

More… ↓

⤷  Try for Free

Details for Patent 10,206,910

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 ⤷  Try for Free 2034-11-07
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 ⤷  Try for Free 2034-11-07
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 ⤷  Try for Free 2034-11-07
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 May 18, 2016 ⤷  Try for Free 2034-11-07
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 March 08, 2019 ⤷  Try for Free 2034-11-07
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.